Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell Culture (Optaflu®) in Healthy Adults

NCT01880697 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01880697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01880697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell Culture (Optaflu®) in Healthy Adults
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2013
Completion date
September 30, 2013
Enrollment
126 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human influenza